Financial News

Financial Report: Patheon

Drug Substance Services up 26% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Patheon 3Q Revenues: $482.0 million (+8%) 3Q Earnings: $8.8 million (loss of $21.6 million 3Q15) YD Revenues: $1.4 billion (+3%) YTD Loss: $12.4 million (loss of $9.0 million YTD15) Comments: Drug Product Services (DPS) segment revenue was $309 million in the quarter, up 7% with growth in North America. Pharmaceutical Development Services (PDS) segment revenue was $57 million, up 6% with growth across the network, partially offset by the delay of additional sterile capacity coming...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters